Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression profiling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently downregulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.
Introduction
Epigenetic modifications of the mammalian genome, such as DNA methylation and core histone posttranslational modifications, are now regarded as critical regulators of transcription, embryonic development and genomic imprinting (Bird, 2002) . DNA methylation, occurring at the fifth position of cytosine within cytosine guanine (CpG) dinucleotides, is a potent and heritable gene silencing signal mediated by three DNA methyltransferases, DNMT1, DNMT3A and DNMT3B (Robertson, 2002) . Subsequent 'reading' of the DNA methylation mark is accomplished by a family of methyl-CpG-binding proteins, including MBD1, MBD2, MBD3 and MeCP2 (Bird, 2002; Robertson, 2002) . Intertwined with DNA methylation is a significantly more complex array of post-translational modifications of the core histone N-terminal 'tails', such as phosphorylation, acetylation, methylation and ubiquitination. Acetylation and methylation, particularly of the histone H3 and H4 tails, act as marks of transcriptional activation or repression (Jenuwein and Allis, 2001 ). The DNA methylation and histone modification machineries interact with each other and cooperate to establish the full set of epigenetic marks throughout the genome (Robertson, 2002) .
Proper control of epigenetic modifications is critical to regulating cell growth. Numerous studies have shown that DNA methylation patterns are globally disrupted in tumor cells. The genomes of cancer cells are hypomethylated overall and concomitantly demonstrate regional hypermethylation events (Jones and Baylin, 2002) . Hypomethylation leads to genomic instability (another hallmark of transformed cells) by loss of DNA methylation from within the repetitive fraction of the genome and increased mitotic recombination (Chen et al., 1998) . Region-specific hypermethylation events, occurring primarily at CpG islands, which are normally methylation free, result in long-term silencing of the associated gene. DNA methylation-mediated silencing of growth-regulatory genes therefore acts in a manner akin to genetic changes leading to loss of cell growth control and contributing directly to tumorigenesis (Jones and Baylin, 2002 ). Recent studies demonstrate that histone acetylation and histone methylation are also globally disrupted in tumor cells (Fraga et al., 2005) . Importantly, unlike genetic changes, epigenetic changes are reversible with currently available DNA methylation (5-aza-2 0 -deoxycytidine (5-azadC)) and histone deacetylase (HDAC) inhibitors (trichostatin A (TSA)) and these agents act synergistically to restore expression of silenced genes, re-establish growth control or induce apoptosis, and they demonstrate antitumor activity in human cancer patients (Cameron et al., 1999; Jones and Baylin, 2002; Schrump and Nguyen, 2005) .
Cancer arises from a complex combination of genetic and epigenetic abnormalities. Lung cancer, now the leading cause of cancer-related deaths for both men and women in the United States, is no exception and factors contributing to this deadly disease have been extensively studied (Digel and Lubbert, 2005; Schrump and Nguyen, 2005) . Lung cancers are classified as either small-cell carcinomas or non-small-cell lung cancers (NSCLC, the more common form). One of the most common genetic alterations in NSCLC is deletion of the short arm of chromosome 3, resulting in loss of the FHIT, RASSF1A and b-catenin growth regulatory genes (Digel and Lubbert, 2005) . Numerous epigenetic defects have also been found in NSCLC samples, many targeting the same genes that are inactivated by genetic mechanisms (Maruyama et al., 2004) . Mortality rates approaching 86% are associated with lung cancer and this is, in large part, due to the fact that many patients present with advanced-stage disease (Belinsky, 2004) . There is currently no validated screening approach for the early detection of lung cancer as there is for other tumor types like colon, prostate and breast.
The study of epigenetic changes in lung cancer has the potential to advance our understanding of its etiology as well as provide novel early detection biomarkers. Aberrant CpG island hypermethylation events, such as methylation of the p16
INK4a tumor suppressor gene, occur very early in tumorigenesis and are detectable in blood and sputum of cancer patients, making them attractive as a screening tool (Belinsky et al., 1998) . Methylated p16
INK4a alleles were detectable in nearly 20% of biopsy specimens from smokers without cancer (Nuovo et al., 1999) . Interestingly, inhibition of DNA methylation and histone deacetylation in a mouse model of lung cancer resulted in a >50% reduction in lung tumor development, supporting the notion that the epigenetic changes seen in human tumors are relevant to disease progression (Belinsky et al., 2003) .
In order to gain a more complete understanding of the contribution of aberrant gene silencing mediated by epigenetic mechanisms to lung cancer development, we employed high-throughput gene expression microarrays combined with pharmacologic inhibition of DNA methylation and histone deacetylation in NSCLC cell lines. Our analysis uncovered over 200 genes upregulated by 5-azadC and TSA treatment. Interestingly, although some of these were clearly regulated by DNA methylation, including metallothionein 3 (MT3), cystatin E/M (CST6) and the imprinted neuronatin (NNAT) gene, others were regulated by histone deacetylation alone, such as the activating transcription factor 3 (ATF3), cylindromatosis (CYLD) and CD9 genes. Importantly, genes showing aberrant promoter methylation in cell lines were hypermethylated and downregulated in primary lung tumors. HDAC-regulated genes were also found to be downregulated in primary tumors and chromatin immunoprecipitation (ChIP) experiments revealed that their promoter regions possess properties characteristic of repressive chromatin. Colony formation experiments indicate that most of the genes we tested suppress the growth of lung tumor cells, suggesting that they function as tumor suppressor genes. This study therefore provides a large number of potential candidate genes representing both novel growth regulatory genes and potential disease biomarkers for NSCLC.
Results
Identification of genes induced by DNA methylation and histone deacetylation in lung cancer cell lines Although many genes subject to epigenetic silencing have been identified in lung cancer, a systematic and unbiased genome-wide screen for such genes has not, to our knowledge, been reported. We therefore treated four NSCLC cell lines (A549, NCI-H358, NCI-H292, A427) with 5 mM 5-azadC for 4 days, followed by a 24 h treatment with 100 nM TSA. This approach was used to maximize the number of reactivated genes, as these two agents have been shown to act synergistically in lung and other tumor types to reactivate silenced genes and suppress tumor growth (Cameron et al., 1999; Belinsky et al., 2003) . Changes in gene expression were determined using the Affymetrix U-133A GeneChip. This array allows for the analysis of expression of approximately 14 500 well-validated transcripts. Two independent preparations of untreated and treated RNA were prepared from each cell line, labeled and hybridized to separate arrays. The data were analysed via SAM software. Significant changes in gene expression were observed following 5-azadC and TSA treatment. Most of the changes, as expected, were in the form of increased gene expression (226 genes upregulated, false discovery rate (FDR) ¼ 1%); however, there were also genes that were downregulated by the drug treatment (85 genes, FDR ¼ 1%). The complete list of genes can be found in Online Supplementary Table S1 . Genes in this list are involved in diverse cellular functions. Upregulation of numerous cancer-testis genes (MAGE-A9, -B1, -B2 and -C1) that are known to be methylated in normal cells, but which undergo demethylation in many types of cancer (Schrump and Nguyen, 2005) , genes in the interferon pathway (STAT3, IFI30 and IRF7) (Karpf et al., 1999) , the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 (Eickoff et al., 2000) and several growth/metastasis regulating genes (MMP-2 and WIF-1 (10% FDR gene list)) known to be hypermethylated in lung or other tumor types (Sato et al., 2003; Mazieres et al., 2004) serve to validate our methodology.
Expression analysis of select genes in NSCLC cell lines and determination of their response to individual drug treatments In order to focus on the genes most likely to be frequent targets of epigenetic silencing in lung cancer, we imposed the additional criteria that the gene be upregulated in at least three out of four cell lines and possess a CpG island within its 5 0 -regulatory region. Upregulation of genes lacking a CpG island may also be relevant, but they were not studied further as part of this analysis. This reduced the number of genes to 58 and we then designed primers for these genes to confirm our microarray expression data using semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) (Figure 1a and data not shown). Based on these results we focused our analysis on nine genes, neuronatin (NNAT), metallothionein 3 (MT3), cystatin E/M (CST6), RAS guanyl releasing protein 2 (calcium and DAGregulated, RASGRP2), nuclear receptor interacting protein 3 (NRIP3), the cylindromatosis gene (CYLD), the CD9 antigen gene, activating transcription factor 3 (ATF3), and the oxytocin receptor (OXTR). Properties of these genes are summarized in Table 1 . Pubmed searches indicated that none of them have been shown to be a target for epigenetic silencing in lung cancer. To obtain a better estimate of the frequency of epigenetic silencing of these nine genes in NSCLC cell lines, we performed semiquantitative RT-PCR in the original four cell lines used in the microarray screen and five additional cell lines, NCI-H23, NCI-H522, NCI-H1299, NCI-H322 and NCI-H460, and a sample of normal lung from an individual without cancer (Figure 1 ). Figure 1a shows that the expression of all nine genes was readily detectable in normal lung, but was downregulated in nearly all of the cell lines. In all cases where the gene was downregulated, treatment of cells with 5-azadC and TSA resulted in robust re-expression or a significant increase in expression over the basal level (Figure 1a) .
A summary of all of the expression studies is presented in Table 2 .
In our initial microarray screen, we treated cells with both 5-azadC and TSA; therefore, it remained possible that NNAT, MT3, CST6, RASGRP2, NRIP3, CYLD, CD9, ATF3 and OXTR may be regulated by DNA methylation, histone acetylation or both. To determine which epigenetic mechanism was dominant, we treated NCI-H358 cells (or A549 cells for CST6 analysis) with 5 mM 5-azadC alone for 4 days and 100 nM TSA alone for 24 h and prepared RNA for expression analysis. Results showed that NNAT, MT3, CST6 and RASGRP2 are strongly induced by 5-azadC alone, but not by TSA, suggesting that they are regulated by DNA methylation. Interestingly, NRIP3, CYLD, CD9, ATF3 and OXTR were strongly induced by TSA alone. 5-azadC had little to no effect on the expression of these five genes ( Figure 1b) . We obtained similar results using the NCI-H292 cell line (data not shown). Taken together, these results suggest that our microarray screen successfully identified genes regulated by DNA methylation and histone deacetylation and, somewhat unexpectedly, silencing by histone deacetylation was nearly as common as silencing by DNA hypermethylation in this panel of nine genes.
Analysis of DNA methylation patterns in the promoter regions of genes silenced by epigenetic mechanisms in NSCLC cell lines Induction of transcription in the presence of 5-azadC or TSA strongly suggests that a gene is regulated by DNA methylation or histone deacetylation, respectively; however, it remains possible that such effects are indirectly mediated by induction of other transcriptional regulators or loss of repressor function. To distinguish between these two possibilities, we designed methylation-specific PCR (MSP) primers within the CpG island promoter Figure 1 (a) Confirmation of microarray expression data by semiquantitative RT-PCR. Expression of the nine genes chosen for study (listed at the left) was analysed in nine NSCLC cell lines before (À) and after treatment with 5 mM 5-azadC (4 days) and 100 nM TSA (final 24 h) ( þ ). Also shown is expression of each of the genes in a sample of normal lung. (b) Examination of the effects on gene expression with individual drug treatments. NCI-H358 cells were untreated (À), treated with 5 mM 5-azadC alone for 4 days ('A'), 100 nM TSA alone for 24 h ('T') or both drugs ('A þ T') and the expression of the nine genes was monitored by RT-PCR. A549 cells were used for analysis of CST6 expression, as it is expressed in untreated NCI-H358 cells. GAPDH served as a loading control. RT-PCR reactions were resolved on 2% agarose gels.
Epigenetic silencing in non-small-cell lung cancer S Zhong et al Epigenetic silencing in non-small-cell lung cancer S Zhong et al regions of each of the nine genes in Figure 1 . MSP is a semiquantitative PCR-based method for determining methylation status of CpG sites within a primer binding site using sodium bisulfite-modified genomic DNA as a template (Herman et al., 1996) . We first determined the methylation status of all nine genes in normal lung and MSP revealed that all are unmethylated with the exception of NNAT (Figure 2 ). NNAT showed an equal mixture of methylated and unmethylated alleles, consistent with the fact that it is an imprinted gene. NNAT is expressed exclusively from the paternal allele in humans (Evans et al., 2001) . MSP analysis of the NSCLC cell lines revealed hypermethylation of NNAT and MT3 in all cases and hypermethylation of CST6 in nearly all cases ( Figure 2 ). De novo methylation of the unmethylated paternal allele of NNAT is also referred to as loss of imprinting (LOI) (Feinberg and Tycko, 2004) . RASGRP2 showed partial methylation in three cell lines and NRIP3 was fully methylated in one cell line and partially methylated in four others. With the exception of NRIP3, these data are consistent with the expression studies showing that 5-azadC alone mediates re-expression of these genes. Regulation of NRIP3 may be more complex, as discussed below. MSP analysis of CYLD, CD9, ATF3 and OXTR indicated that these genes were completely unmethylated in all cell lines ( Figure 2 , Table 2 ). This result is consistent with the expression analysis in Figure 1b , which clearly showed that TSA treatment alone mediated upregulation of these genes in the NCI-H358 cell line. We next analysed DNA methylation patterns in the promoter regions of NNAT, MT3, CST6, RASGRP2, NRIP3, CYLD and ATF3 in greater detail using bisulfite genomic sequencing (BGS) in the NCI-H358 or A549 cell lines and in normal lung tissue. BGS, like MSP, makes use of sodium bisulfite-modified genomic DNA as a template for PCR. For BGS, however, the PCR primers do not contain CpG sites, so that they amplify the template in an unbiased manner and the methylation status of all CpG sites between the two primers is determined (Frommer et al., 1992) . BGS data are summarized in Figure 3 . With the exception of NNAT, all genes were hypomethylated in normal lung tissue indicating that promoter hypermethylation is not part of their normal biology. BGS for NNAT yielded a roughly equal number or fully methylated and fully unmethylated clones, consistent with it being imprinted (Evans et al., 2001) . The promoter/CpG island regions of NNAT, MT3, CST6, RASGRP2 and NRIP3 were highly methylated in NCI-H358 cells (or A549 cells for CST6), consistent with both the expression and the MSP studies. RASGRP2 was more highly methylated by BGS than by MSP. This may be because the BGS region is located further upstream of the transcription start site than the MSP region, owing to limitations wherein we could design efficient and specific MSP primers (Figure 3 ). BGS analysis of NRIP3 revealed that it was generally hypermethylated toward the 5 0 -end of the region analysed, but was hypomethylated near the 3 0 -end of the BGS region. These results are consistent with the MSP data, generated slightly further 3 0 to the BGS region, which showed that NRIP3 was hypomethylated in NCI-H358 cells. We were unable to design BGS primers that overlapped with the MSP region for NRIP3. In contrast, the CYLD and ATF3 promoter regions were completely devoid of methylation in NCI-H358 cells (Figure 3) , consistent with the MSP data. The CD9 and OXTR promoters in NCI-H358 cells were also unmethylated by BGS (data not shown). Taken together, the expression and DNA methylation analyses (summarized in Table 2 ) allow our panel of nine epigenetically regulated NSCLC genes to be divided into two classes, those regulated by DNA methylation (NNAT, MT3, CST6, RASGRP2 and NRIP3) and those regulated by histone deacetylation (CYLD, CD9, ATF3 and OXTR). Although regulation of NRIP3 appears to be more complex and may involve both mechanisms, we have grouped it into the DNA methylation-regulated Figure 2 DNA methylation analysis of the nine epigenetically regulated genes using MSP. Primers specific for unmethylated DNA (U) or methylated (M) DNA were designed within the CpG island promoter regions of each gene (see also Figure 3 for locations of the primers) and used in semiquantitative PCR reactions with bisulfite-modified genomic DNA. All reactions were repeated at least three times and a representative gel image is shown.
Epigenetic silencing in non-small-cell lung cancer S Zhong et al genes, because it demonstrates hypermethylation in nearly half of the tumor cell lines (by MSP), whereas the HDAC target genes are unmethylated in all cases examined.
Methylation and expression analysis of epigenetically regulated genes in primary lung tumor tissue We next extended our analysis to primary snap-frozen lung tumors in order to validate the cell line data and to estimate the frequency of epigenetic silencing of these genes in primary samples. We analysed the methylation status of all nine genes in 19 tumors, 15 of which had matched adjacent normal tissue available. DNA methylation was analysed using MSP and representative MSP results from normal lung and two tumor/normal pairs are shown in Figure 4a . All genes, with the exception of NNAT, were hypomethylated in both normal lung from a disease-free individual and the matched adjacent normal tissues in the majority of the cases. We found that the frequency of promoter hypermethylation in the tumor tissues was 68, 50, 0, 32, 0, 13, 0 and 6%, respectively, for MT3, CST6, RASGRP2, NRIP3, CYLD, CD9 ATF3 and OXTR (summarized in Table 2 ). Therefore, although we did not find any examples of promoter hypermethylation in cell lines for CD9 and OXTR, we did detect it in a small number of primary tumors. In many cases, we found a mixture of methylated and unmethylated alleles by MSP in the tumor samples (see MT3 in Figure 4a ) and the unmethylated alleles are most likely due to contamination of the tumor mass with adjacent normal tissue or from infiltrating inflammatory cells. NNAT was approximately 50% methylated in the majority of the normal tissues, as expected for an imprinted gene, and underwent LOI in 64% of the tumors ( Figure 4a and Table 2 ). Aberrant hypermethylation was rare in adjacent normal tissues in most cases, however, we detected LOI of NNAT in 20% of these (Table 2) . LOI at a similar frequency in adjacent normal colorectal tissue has been reported for the imprinted IGF2 gene in colorectal cancer patients (Cui et al., 2003) . Taken together, our MSP analysis indicates that the DNA methylation target genes NNAT, MT3 and CST6 are subject to hypermethylation in over 50% of the primary tumors, whereas NRIP3 methylation is less common and RASGRP2 was not methylated in any of the tumors. In addition, the HDAC target genes were either methylated at very low frequency or not at all in the primary tumors, consistent with the cell line data. Semiquantitative RT-PCR was then used to determine if the nine genes in our panel were downregulated in tumor relative to adjacent normal tissue. Eight tumors and four adjacent normal tissues yielded RNA in sufficient quantity and quality to be analysed. Representative RT-PCR from two tumor/normal pairs is shown in Figure 4b . Expression of NNAT, MT3, CST6, RASGRP2, NRIP3, CYLD, CD9, ATF3 and OXTR was downregulated in the tumor sample relative to the normal in 75, 100, 62, 88, 50, 63, 88, 75 and 63% of cases, respectively ( Figure 4b and Table 2 ). Interestingly, BLCAP which also contains a CpG island within its promoter region, is not imprinted (Evans et al., 2001 ), and we found that, whereas NNAT is downregulated in tumors, BLCAP expression is unchanged, indicating that the DNA methylation defect in NNAT is highly localized (Figure 4b ). For tumors with no matched normal, we considered these to be downregulated if expression was reduced threefold or more relative to at least three out four of the normal tissue samples. As there was little to no methylation found at the HDAC target genes by MSP, and it was not possible to analyse responsiveness of tumor cells to TSA or to perform ChIP using frozen tissue, RT-PCR expression analysis was key to supporting the notion that these genes are epigenetically regulated. Indeed, we found that these four genes were downregulated in over 60% of the tumor samples. Although not direct proof that they are regulated by histone deacetylation in primary tumors, the methylation and expression analyses are consistent with this mechanism.
Effects of DNA methylation and HDAC target gene expression on NSCLC growth Growth-suppressive effects have been demonstrated for MT3, CST6, CYLD, ATF3 and OXTR in other systems (elaborated upon in the discussion). To our knowledge, the functional effects of ectopic expression of the nine genes in our panel have not been investigated in NSCLC. To examine this, we used a colony formation assay. NCI-H358 cells, which express low or undetectable levels of the genes under study (except for CST6, for which A549 cells were used), were transfected with plasmid vectors expressing NNAT, MT3, CST6, RASGRP2, NRIP3, CYLD, CD9 or ATF3. We also employed a mutant form of CYLD in which its C-terminal ubiquitin-specific protease domain, which is critical for its tumor suppressor function, has been deleted (Trompouki et al., 2003) . OXTR was not examined in this assay. Transfection of cells with empty expression vector served as a positive control for growth and all other constructs were set relative to this value. Transfection of the p16 INK4a tumor suppressor gene served as a positive control for growth suppression. We found that expression of NNAT, RASGRP2, MT3, ATF3, full-length CYLD and CST6 markedly suppressed NSCLC cell growth ( Figure 5 ). Consistent with previous results, deletion of amino acids 538-953 of CYLD resulted in loss of its growth-suppressive effects. ATF3 expression caused the most profound suppression of cell growth. CD9 and NRIP3 did not suppress the growth of NCI-H358 cells (Figure 5 ), indicating that they may not play roles in cell growth or, more likely, that their activity cannot be measured using the colony formation assay. Similar results were obtained using the NCI-H292 cell line (data not shown).
HDAC inhibitors and histone tail modifications in the regulation of HDAC target genes
To obtain further support that the HDAC target genes were indeed regulated by histone modification patterns, Figure 4 Analysis of epigenetically regulated genes in primary lung tumor samples. (a) Representative MSP DNA methylation analyses from normal lung tissue and two frozen lung tumor (T)/adjacent normal (N) tissue pairs (nos. 22 and 50) for nine genes. The normal lung in the latter cases was taken from the surgical margin. Samples were considered methylated if there was amplification with the 'M' primers. In the case of NNAT, samples were scored as positive for LOI if the unmethylated fraction was lost. (b) Representative expression results from two frozen lung tumor/normal pairs using semiquantitative RT-PCR. The BLCAP gene, in which the entire NNAT gene is embedded, served as control to demonstrate that the NNAT methylation and expression defect was highly localized. GAPDH served as a loading control for sample integrity. All reactions were repeated at least three times before being scored.
Epigenetic silencing in non-small-cell lung cancer S Zhong et al we treated NCI-H292 cells with increasing doses of TSA (50, 100 and 200 nM) and another HDAC inhibitor, valproic acid (VPA, 1, 5 and 10 mM), for 24 h. TSA is a member of the hydroxamic acid-based family of HDAC inhibitors and VPA is a member of the short-chain fatty acid class of HDAC inhibitors (Somech et al., 2004) . We focused this study on the HDAC target genes and also analysed NRIP3 given that it showed features of both classes. TSA and VPA induced the expression of CYLD, ATF3, OXTR, CD9 and NRIP3 in a dose-dependent manner (Figure 6a ). ATF3 is induced by many forms of cellular stress; however, it was not upregulated following treatment with the topoisomerase II inhibitor etoposide (Figure 6b) , indicating the ATF3 upregulation we observe is unlikely to be attributable to nonspecific cytotoxic effects. None of the other genes were affected by etoposide treatment. The cells remained greater than 90% viable under the treatment conditions employed (data not shown). The induction of the HDAC target genes by two different classes of HDAC inhibitors in a dose-responsive manner supports the interpretation that they are regulated by histone acetylation status in NSCLC cells.
We examined the role of histone tail modifications further using ChIP. NCI-H292 cells were treated with 200 nM TSA for 24 h, fixed with formaldehyde and the chromatin isolated and sheared by sonication. This chromatin was used in immunoprecipitations with antibodies specific for acetylated histone H4 (recognizing H4 acetylated at lysines 5, 8, 12 and 16), histone H3 dimethylated at lysine 4 and histone H3 dimethylated at lysine 9. The former two modifications are characteristic of transcriptionally permissive chromatin, whereas the latter is characteristic of repressed chromatin (Jenuwein and Allis, 2001) . Results indicate that, in general, all of the HDAC target genes demonstrate low or undetectable levels of histone modifications associated with active chromatin (H4 acetylation and H3 K4 dimethylation). However, these modifications were increased following TSA treatment, and conversely, elevated levels of the repressive H3 K9 methylation modification were reduced following TSA treatment, a condition that INK4a expression vectors) were transfected into A549 cells (wells to the right of the dashed line). The expression vector also encoded neomycin resistance. Following the transfection, cells were placed in 800 mg/ml G418 for 9-14 days to kill untransfected cells. Colonies were stained with methylene blue and counted. 'Mock' is a transfection without plasmid and is a positive control for cell killing by G418. Transfection of a p16
INK4a expression vector served as positive control for growth suppression. All transfections were repeated three times and a representative image is shown. (b) Quantitation of the number of colonies forming after transfection with each of the indicated plasmids relative to the empty vector control (set at 100%). Values are the average of three independent experiments and the bar is the s.d. CYLD DC-term is a deletion of amino acids 538-953.
Epigenetic silencing in non-small-cell lung cancer S Zhong et al correlates with upregulation of gene expression (Figure 6c ). The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a negative control and showed high levels of the active chromatin modifications, undetectable levels of the repressive chromatin modification, and these were unchanged by TSA treatment. These results therefore support our classification of CYLD, ATF3, OXTR and CD9 as HDAC-regulated genes.
Role of individual DNA methyltransferases in mediating promoter hypermethylation.
Although there is a degree of redundancy in the division of labor among DNMT1, DNMT3A and DNMT3B in methylating the genome, increasing evidence suggests that there is functional specialization as well (Gius et al., 2004) . To determine which of the DNMTs mediate the aberrant promoter hypermethylation of the genes we have identified, we employed a model cell line system, namely the HCT116 colon cancer cell line and its isogenic derivatives, in which the DNMT1 (1 KO), DNMT3B (3B KO) and DNMT1 and DNMT3B (double knockout (DKO)) genes have been disrupted by homologous recombination (Rhee et al., 2002) . Similar to what we found in NSCLC cell lines, parental HCT116 cells expressed low or undetectable levels of NNAT, MT3, RASGRP2, NRIP3, CYLD, CD9, ATF3 and OXTR ( Figure 7a ). CST6 expression was readily detectable in parental HCT116 cells; therefore, it was not further analysed (data not shown). In addition, the promoter regions of NNAT, MT3, RASGRP2 and NRIP3 were hypermethylated by MSP (Figure 7b ), supporting our assertion that HCT116 cells are a valid model system. NNAT and NRIP3 were re-expressed only if both DNMT1 and DNMT3B were inactivated (Figure 7a ), suggesting that these two DNMTs cooperate to establish methylation at these regions. MT3 was re-expressed in both the DNMT1 and the DKO cells, indicating that DNMT1 is likely the predominant methylating enzyme for this region. RASGRP2 was reexpressed in all three knockouts, but most strongly in the DNMT3B knockout cells (Figure 7a ). Interestingly, although the HDAC target genes CYLD, CD9, ATF3 and OXTR were unmethylated in HCT116 cells and all of the knockouts (Figure 7b ), as expected from the NSCLC analysis, all four genes were upregulated in the DNMT1 KO cells (Figure 7a ). Although this may be due to nonspecific effects (reduced expression of a repressor for example), it may also arise from chromatin structural changes, as DNMT1 KO HCT116 cells display globally increased levels of histone H3 lysine 9 acetylation (a marker of gene activation) and reduced levels of methylation at this same residue (a marker of repressed chromatin) (Espada et al., 2004) . Therefore, Epigenetic silencing in non-small-cell lung cancer S Zhong et al results obtained with the HCT116 DNMT1 KO cells indirectly support the notion that the genes we have defined as HDAC targets are regulated by histone acetylation, consistent with our TSA and ChIP studies ( Figure 6 ). These findings also suggest that the epigenetically regulated genes we identified in NSCLC cells may also be targeted for silencing in other tumor types.
Discussion
In this paper, we have identified over 200 epigenetically regulated genes in NSCLC cell lines using pharmacologic inhibitors of DNA methylation and histone deacetylation combined with gene expression microarrays, and have studied nine of these in detail. Functional studies revealed that the nine genes could be divided into two groups, those regulated by DNA methylation (NNAT, MT3, CST6 and RASGRP2) and those regulated by histone deacetylation (CYLD, CD9, ATF3 and OXTR), whereas NRIP3 exhibited some properties of both. Three of the DNA methylation target genes were hypermethylated in nearly all NSCLC cell lines and in 50-70% of primary tumors. Both DNA methylation and HDAC target genes were downregulated in nine NSCLC cell lines and in over 60% of primary tumors, with five of the genes downregulated in 75% or more of the primary tumors. In addition, ectopic expression of NNAT, RASGRP2, MT3, CST6, ATF3 and CYLD significantly suppressed the growth of NSCLC cells in culture, suggesting that they act as tumor suppressor genes. ChIP assays and the use of two structurally unrelated HDAC inhibitors lent additional support that our experimental approach successfully identified genes dominantly regulated by histone acetylation. The nine genes we have studied in detail in this report therefore represent new lung cancer growth regulatory genes, the study of which may lead to novel insights into the etiology of NSCLC and provide new therapeutic targets.
Interestingly and unexpectedly, over half of the genes we selected for characterization were dominantly regulated by histone deacetylation rather than DNA methylation. HDAC target genes were, in general, expressed at a low level in untreated cells, in contrast to the DNA methylation target genes, whose expression was nearly undetectable even at high PCR cycles. We believe, however, that the downregulation of the HDAC target genes has functional significance for tumor growth because ectopic expression of two of them resulted in profound growth suppression (CYLD and ATF3). HDAC inhibitors are currently being extensively evaluated in clinical trials (Schrump and Nguyen, 2005) . They have shown great promise in tissue culture and mouse model systems. HDAC inhibitors induce the expression of the p21 WAF1/CIP1 cell cycle regulatory gene, which mediates, at least in part, their ability to induce G1 arrest (Eickoff et al., 2000) . Use of HDAC inhibitors alone, or in combination with 5-azadC, for the treatment of NSCLC and other cancers is also being evaluated in several clinical trials (Schrump and Nguyen, 2005) . Regardless of whether these epigeneticbased chemotherapies are effective when given alone, there is also significant interest in combining them with conventional chemotherapeutic agents. For example, HDAC inhibitors enhanced the cytotoxicity of DNAbinding drugs like VP-16 (Kim et al., 2003) . Further work will be necessary to determine the full extent of HDAC-regulated genes and whether gene silencing via this mechanism is more prevalent in certain tumor types or is a universal feature of all tumors. Certain genes, such as the transcriptional regulator ATF3 (Yan et al., 2005 ) that we identified, may 'reprogram' cancer cells in a way that renders them more susceptible to killing by other non-epigenetic therapies.
Based on the microarray analysis and follow-up DNA methylation studies, we classified NNAT, MT3, CST6, RASGRP2 and NRIP3 as DNA methylation target genes. NNAT is a paternally expressed imprinted gene (Evans et al., 2001) . Based on its structure and localization to the endoplasmic reticulum, NNAT may be involved in regulating intracellular calcium levels. Indeed, ectopic expression of NNAT stimulated 3T3-L1 adipocytes to differentiate into mature adipocytes by increasing intracellular calcium levels and enhancing cAMP-responsive element-binding protein (CREB) phosphorylation (Suh et al., 2005) . NNAT was found to undergo LOI in 69% of leukemia samples in one study, although its effects on cell growth were not analysed (Kuerbitz et al., 2002) . LOI of NNAT in 20% of the adjacent normal tissues we examined suggests that this may represent a preneoplastic alteration, as has been observed for other imprinted genes like IGF2 in colon cancer (Cui et al., 2003) . MT3 was also subject to Epigenetic silencing in non-small-cell lung cancer S Zhong et al DNA methylation-mediated silencing in 100% of NSCLC cell lines and nearly 70% of the primary tumors. MT3 belongs to a family of small, cysteine-rich transition metal-binding proteins. Ectopic expression of MT3 inhibits the growth of prostate cancer cells (Dutta et al., 2002) and reduced MT3 expression is characteristic of metastatic lung adenocarcinomas with poor clinical outcome (Ramaswamy et al., 2003) . CST6 is a member of the cystatin family of proteins, which are naturally occurring inhibitors of lysosomal/endosomal cysteine proteases (Abrahamson et al., 2003) . CST6 suppresses the growth and invasiveness of breast cancer cells and is downregulated and hypermethylated in breast cancers at a frequency close to what we have reported here for NSCLC (Ai et al., 2006) . We have also recently found high-frequency CST6 promoter methylation in human glioblastomas, which are a highly invasive type of tumor . As ectopic expression of NNAT, MT3 and CST6 suppressed the growth of NSCLC cell lines, further investigation of the frequency of their epigenetic inactivation in a larger set of tumor samples is warranted. NRIP3 and RASGRP2 were hypermethylated at moderate frequency in NSCLC cell lines, but at relatively low frequency in primary NSCLC tumors. Despite the low frequency of DNA methylation, both genes were downregulated in the majority of cell lines and over 50% of primary tumors. Whereas RASGRP2 was clearly upregulated by 5-azadC treatment alone, NRIP3 was reactivated by TSA treatment. The discrepancy between the DNA methylation and downregulation frequencies suggests that, whereas methylation of these genes in tumors and cell lines does occur, it may not be the predominant mechanism by which they are downregulated. The function of NRIP3 is unknown. RASGRP2 is a member of a group of diacylglycerol-dependent guanosine diphosphate/ guanosine triphosphate exchange factors that catalyse nucleotide exchange on Rap1, N-and Ki-Ras (ClydeSmith et al., 2000) . Ras proteins transduce signals from activated cell surface receptors through diverse pathways inducing oncogenic transformation or cell cycle arrest and differentiation. To our knowledge, its effects on the growth of human cells has not been investigated and it will be of interest to determine exactly how it regulates growth of NSCLC cells.
The HDAC target genes we identified include ATF3, CYLD, CD9 and OXTR. They were unmethylated in all NSCLC cell lines and nearly all of the primary tumors, yet their expression was markedly downregulated in untreated cell lines and primary tumors. ATF3 is a member of the ATF/CREB family of transcription factors that can activate or repress transcription. ATF3 is induced by many forms of cellular stress, such as ischemia, nutrient deprivation and genotoxic agents (Hai et al., 1999) and is downregulated in both colon and lung tumors (Garber et al., 2001; Bottone et al., 2003) , consistent with our data. Another HDAC target gene, CYLD, is a known tumor suppressor mutated in the autosomal-dominant disease cylindromatosis, which is characterized by multiple neoplasms of the skin appendages and the head/neck region (Bignell et al., 2000) . CYLD is a deubiquitinating enzyme that negatively regulates cytokine-mediated activation of nuclear factor-kB via the tumor necrosis factor receptors. CYLD expression promotes apoptosis in breast cancer cells and its deubiquitinating activity is essential for this function (Wang et al., 2005) . Our studies demonstrated for the first time that CYLD is frequently downregulated in NSCLC by epigenetic mechanisms, suggesting that it plays an important role in the genesis of this tumor type.
CD9 and OXTR, also HDAC target genes, were rarely methylated in the NSCLC cell lines and tumors, but were downregulated in a large fraction of primary tumors (88 and 63%, respectively). CD9 is involved in signal transduction by virtue of its ability to form complexes with other cell surface proteins (Maecker et al., 1997) . CD9 is downregulated in lung tumor metastases relative to the primary tumor and loss of CD9 expression correlates strongly with reduced survival (Higashiyama et al., 1995) . Our results suggest that this downregulation is likely due, in large part, to epigenetic mechanisms and the induction of genes like CD9 by HDAC inhibitors in lung cancer patients may have the added benefit of inhibiting metastasis. OXTR is a G-protein-coupled transmembrane receptor that binds the nonapeptide oxytocin (OT). OT is involved in many normal biological functions and it also regulates the growth of neoplastic cells. For example, OT signaling inhibits the growth of ovarian, neuroblastoma, astrocytoma and other cell types (Cassoni et al., 2004) . It was also reported that OXTR expression is reduced in approximately 50% of NSCLC tumors as monitored by immunohistochemistry, consistent with our findings (Pequeux et al., 2005) .
The frequency of aberrant DNA methylation at the MT3, CST6 and NNAT promoters was comparable to or greater than the methylation frequencies reported for other more commonly studied tumor suppressor genes subject to epigenetic silencing, such as p16 INK4a (13-70% of NSCLC), MGMT (19-47% of NSCLC) and RASS-F1A (30-38% of NSCLC) (Belinsky, 2004 , and references therein). These three genes may therefore represent new biomarkers for lung cancer, and in future studies, it will be critical to correlate methylation status with clinical outcome. The use of aberrant DNA methylation as an early detection marker has shown significant initial promise (Belinsky, 2004) . Hypermethylation of tumor suppressor genes, such as GSTP1, MGMT, DAPK and RASSF1A, in lung cancer patients has been detected using sputum and serum (Esteller et al., 1999; Topaloglu et al., 2004) . In addition, hypermethylated circulating tumor DNA may be useful for monitoring the efficacy of adjuvant therapy or predicting disease relapse (Fiegl et al., 2005) . Although much focus is being placed in DNA hypermethylation as a biomarker, emerging methods for analysing histone modifications may eventually make determination of such modifications at particular genes in tumor tissue amenable to routine analysis (Fraga et al., 2005) . Our current work characterized multiple new DNA methylation and HDAC target genes and uncovered over 200 other potential targets in NSCLC. These data should therefore significantly add to our repertoire or future biomarkers of lung cancer and provide new insights into its etiology.
Materials and methods
Cell lines, tissue culture and drug treatments The NSCLC lines A549, NCI-H358, NCI-H292, A427, NCI-H23, NCI-H522, NCI-H1299, NCI-H322 and NCI-H460 were purchased from the American Type Culture Collection and maintained in McCoy's 5-a medium (Mediatech, Herndon, VA, USA) supplemented with 2 mM L-glutamine and 10% fetal bovine serum (Hyclone, Logan, UT, USA). The HCT116 parental, DNMT1 (1 KO), DNMT3B (3B KO) and DKO cells were provided by Bert Vogelstein (The Johns Hopkins University) (Rhee et al., 2002) . Cell lines were treated with 5 mM 5-azadC for 4 days (fresh drug was added every 24 h), followed by a 24-h treatment with 100 nM TSA. In some cases, treatment with only one drug at the same concentration and time was also performed. All chemicals were purchased from Sigma (St Louis, MO, USA).
Tumor specimens
Fresh-frozen tumors were obtained from the University of Florida Shands Cancer Center Molecular Tissue Bank and Oncomatrix (cases OM-1748, OM-1790, OM-1932 , OM-2096 and OM-2227 . All specimens and pertinent patient information were treated in accordance with policies of the Institutional Review Board of the University of Florida Health Sciences Center. Tumors were analysed by a surgical pathologist. Samples included nine adenocarcinomas (including one tumor that was classified as a 60/40% mixture of adenocarcinoma and large-cell neuroendocrine carcinoma, respectively), five squamous cell carcinomas, three large-cell carcinomas, one malignant fibrous tumor and one pleomorphic liposarcoma that had metastasized to the lung. Only two tumors (one adenocarcinoma and one large-cell carcinoma) were lymph node positive for metastatic tumor (lymph nodes were unavailable for our study). Matched adjacent normal tissue was available for 15 of the tumor samples. RNA and DNA were prepared from tissues as described previously . Two normal lung DNA samples from cancer-free individuals were purchased from BioChain (Hayward, CA, USA). Normal tissue RNA samples were purchased from Clontech (Mountain View, CA, USA) and Ambion (Austin, TX, USA).
Expression microarrays, data analysis and RT-PCR Microarray analysis was performed exactly as described , using the Affymetrix U-133A GeneChip, at the University of Florida's Interdisciplinary Center for Biotechnology Research Gene Expression Core Facility. We identified genes considered significantly affected by treatment at both the 1 and 10% FDR and genes chosen for further study were drawn from both the 1 and 10% FDR gene lists. RT-PCR was carried out according to standard protocols and as we have reported previously . The cDNA was used in semiquantitative PCR with the primers listed in Online Supplementary Table S2 . Amplification of GAPDH was used as a loading control. Following PCR, reaction products were resolved on 2% agarose gels and photographed using a BioRad gel documentation system.
Bisulfite genomic sequencing and methylation-specific PCR BGS and MSP were performed essentially as described previously . Refer to Online Supplementary  Table S2 for a complete listing of PCR primer sequences used for BGS and MSP. TaqGold (ABI) DNA polymerase was used for all reactions. DNA sequencing, using the M13 reverse primer, was performed at the University of Florida Center for Mammalian Genetics DNA Sequencing Facility. For MSP, reaction optimization was performed to ensure that the PCR was in the linear amplification range. Primer specificity was validated using human sperm DNA untreated or treated with CpG (SssI) methylase (New England Biolabs, Ipswich, MA, USA) to represent fully unmethylated and fully methylated controls, respectively (data not shown).
Plasmid construction
Expression plasmids for NNAT and NRIP3 were constructed by first amplifying the complete coding region of each gene from HCT116 DKO cell line cDNA using either Herculase or PfuTurbo DNA polymerases according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA). The MT3 coding region was amplified from a plasmid containing the full-length MT3 cDNA purchased from Origene (Rockville, MD, USA). The CST6 expression vector has been described previously . PCR primers (sequences available upon request) were designed to contain the XhoI restriction enzyme recognition site and PCR products were cloned into the XhoI site of the eucaryotic expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA), which also encodes neomycin resistance. The p16
INK4a expression plasmid has been described previously . Expression vectors for RASGRP2, ATF3, CYLD (C-terminal deletion mutant and full-length forms) and CD9 were kindly provided by Xose Bustelo (University of Salamanca), Michael Kilberg (University of Florida), George Mosialos (Institute of Immunology, Alexander Fleming) and Hansoo Lee (Kangwon National University), respectively.
Colony formation assays NCI-H358 or A549 cells were seeded in six-well plates. The following day, they were used in transfections with 5 ml of LT1 (Mirus, Madison, WI, USA) and 2 mg of each of the expression plasmids described above. Forty-eight hours after transfection, the medium was replaced with fresh media containing G418 to kill untransfected cells. Cells were grown for 9-14 days. Once colonies were visible, they were stained with methylene blue and photographed on a BioRad gel documentation system equipped with a white light transilluminator. All assays were repeated at least three times and data are presented as the mean7s.d. Separately, an aliquot of RNA was prepared from transfected cells and the expression of each of the genes was confirmed by RT-PCR (data not shown).
Chromatin immunoprecipitations
ChIP was performed essentially as described (Chen et al., 2004) . Briefly, NCI-H292 and NCI-H358 cells were seeded at 1.5 Â 10 6 /150-mm dish, grown for 72 h and then were treated with TSA for 24 h or were left untreated. Formaldehyde was added to the culture medium to a final concentration of 1% and the reaction was stopped 10 min later by adding 2 M glycine to a final concentration of 0.125 M. Crosslinked chromatin was sheared by sonication using a Branson Sonifier 450. Normal rabbit IgG was used as the nonspecific antibody control. The antibody-bound complex was precipitated by protein A-Sepharose beads (Amersham Biosciences, Piscataway, NJ, USA). A 1 40 dilution of supernatant from the irrelevant antibody served as a positive control (input). The DNA fragments in the immunoprecipitated complex were 
